RPTX
Repare Therapeutics Inc.
Price Chart
No historical data available
Latest Quote
$2.65
+0.00 (+0.00%)
Current Price
| Previous Close | $2.65 |
| Open | $2.64 |
| Day High | $2.65 |
| Day Low | $2.62 |
| Volume | 1,167,676 |
Stock Information
| Shares Outstanding | 43.11M |
| Total Debt | $342K |
| Cash Equivalents | $112.60M |
| Revenue | $11.87M |
| Net Income | $-72.20M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $114.24M |
| EPS (TTM) | $-1.70 |
| Exchange | NMS |
Recent Price History
No history data available. Data will be fetched automatically.
About Repare Therapeutics Inc.
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. As of January 28, 2026, Repare Therapeutics Inc. operates as a subsidiary of Xenotherapeutics Inc.
đ° Latest News
Gilead Sciences Oncology Push Gains Traction With Trodelvy Keytruda Results
Simply Wall St. âĸ 2026-02-03T06:10:52Z
Gilead Sciences, Inc. (GILD): A Bull Case Theory
Insider Monkey âĸ 2026-02-03T00:29:29Z
Sector Update: Health Care Stocks Rise Wednesday Afternoon
MT Newswires âĸ 2025-12-24T17:08:38ZUpdate: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise
MT Newswires âĸ 2025-12-24T14:49:35ZRepare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3
Zacks âĸ 2025-11-14T23:00:02Z
Here's Why Repare Therapeutics (NASDAQ:RPTX) Must Use Its Cash Wisely
Simply Wall St. âĸ 2025-10-30T12:30:19Z
Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. âĸ 2025-08-10T12:06:18Z
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-08-08T12:10:02Z
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm
GuruFocus.com âĸ 2025-07-17T01:30:13Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $53,477,000 | $51,133,000 | $131,830,000 | $7,600,000 |
| Operating Revenue | $53,477,000 | $51,133,000 | $131,830,000 | $7,600,000 |
| Expenses | ||||
| Total Expenses | $145,621,000 | $167,357,000 | $151,626,000 | $116,260,000 |
| Other Income Expense | $-1,496,000 | $-289,000 | $265,000 | $-185,000 |
| Other Non Operating Income Expenses | $-115,000 | $-119,000 | $-43,000 | $-41,000 |
| Net Non Operating Interest Income Expense | $10,391,000 | $13,334,000 | $5,631,000 | $259,000 |
| Operating Expense | $145,621,000 | $167,357,000 | $151,626,000 | $116,260,000 |
| General And Administrative Expense | $29,680,000 | $33,764,000 | $32,560,000 | $26,213,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 |
| Net Interest Income | $10,391,000 | $13,334,000 | $5,631,000 | $259,000 |
| Interest Income | $10,391,000 | $13,334,000 | $5,631,000 | $259,000 |
| Normalized Income | $-83,515,150 | $-93,641,460 | $-29,274,273 | $-106,766,225 |
| Net Income From Continuing And Discontinued Operation | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 |
| Total Operating Income As Reported | $-93,523,000 | $-116,224,000 | $-19,796,000 | $-108,660,000 |
| Net Income Common Stockholders | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 |
| Net Income | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 |
| Net Income Including Noncontrolling Interests | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 |
| Net Income Continuous Operations | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 |
| Pretax Income | $-83,249,000 | $-103,179,000 | $-13,900,000 | $-108,586,000 |
| Special Income Charges | $-1,379,000 | $0 | - | - |
| Interest Income Non Operating | $10,391,000 | $13,334,000 | $5,631,000 | $259,000 |
| Operating Income | $-92,144,000 | $-116,224,000 | $-19,796,000 | $-108,660,000 |
| Per Share | ||||
| Diluted EPS | $-2.00 | $-2.23 | $-0.69 | $-2.83 |
| Basic EPS | $-2.00 | $-2.23 | $-0.69 | $-2.83 |
| Other | ||||
| Tax Effect Of Unusual Items | $-207,150 | $-15,460 | $80,727 | $-2,225 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-88,842,000 | $-114,103,000 | $-18,126,000 | $-107,045,000 |
| Total Unusual Items | $-1,381,000 | $-170,000 | $308,000 | $-144,000 |
| Total Unusual Items Excluding Goodwill | $-1,381,000 | $-170,000 | $308,000 | $-144,000 |
| Reconciled Depreciation | $1,921,000 | $1,951,000 | $1,978,000 | $1,471,000 |
| EBITDA (Bullshit earnings) | $-90,223,000 | $-114,273,000 | $-17,818,000 | $-107,189,000 |
| EBIT | $-92,144,000 | $-116,224,000 | $-19,796,000 | $-108,660,000 |
| Diluted Average Shares | $42,411,085 | $42,093,293 | $41,922,042 | $37,818,115 |
| Basic Average Shares | $42,411,085 | $42,093,293 | $41,922,042 | $37,818,115 |
| Diluted NI Availto Com Stockholders | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 |
| Tax Provision | $1,440,000 | $-9,383,000 | $15,147,000 | $-1,678,000 |
| Restructuring And Mergern Acquisition | $1,379,000 | $0 | - | - |
| Gain On Sale Of Security | $-2,000 | $-170,000 | $308,000 | $-144,000 |
| Research And Development | $115,941,000 | $133,593,000 | $119,066,000 | $90,047,000 |
| Selling General And Administration | $29,680,000 | $33,764,000 | $32,560,000 | $26,213,000 |
| Other Gand A | $29,680,000 | $33,764,000 | $32,560,000 | $26,213,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $151,131,000 | $212,082,000 | $279,517,000 | $288,421,000 |
| Total Assets | $176,506,000 | $253,901,000 | $364,075,000 | $368,715,000 |
| Total Non Current Assets | $5,357,000 | $10,213,000 | $10,096,000 | $17,301,000 |
| Other Non Current Assets | $179,000 | $396,000 | $497,000 | $586,000 |
| Non Current Accounts Receivable | $960,000 | $2,276,000 | - | - |
| Current Assets | $171,149,000 | $243,688,000 | $353,979,000 | $351,414,000 |
| Prepaid Assets | $6,012,000 | $4,749,000 | $5,715,000 | $6,314,000 |
| Receivables | $12,346,000 | $15,312,000 | $4,323,000 | $3,234,000 |
| Other Receivables | $1,746,000 | $4,499,000 | $4,323,000 | $654,000 |
| Taxes Receivable | $10,600,000 | $10,813,000 | $0 | $2,580,000 |
| Cash Cash Equivalents And Short Term Investments | $152,791,000 | $223,627,000 | $343,941,000 | $341,866,000 |
| Cash And Cash Equivalents | $84,717,000 | $111,268,000 | $159,521,000 | $334,427,000 |
| Cash Equivalents | $40,955,000 | $66,806,000 | $42,995,000 | $2,535,000 |
| Cash Financial | $43,762,000 | $44,462,000 | $116,526,000 | $331,892,000 |
| Non Current Deferred Assets | - | - | $0 | $3,620,000 |
| Non Current Deferred Taxes Assets | - | - | $0 | $3,620,000 |
| Other Current Assets | - | - | $5,715,000 | $6,314,000 |
| Debt | ||||
| Total Debt | $1,933,000 | $3,410,000 | $5,428,000 | $7,313,000 |
| Long Term Debt And Capital Lease Obligation | $88,000 | $1,010,000 | $3,257,000 | $5,592,000 |
| Current Debt And Capital Lease Obligation | $1,845,000 | $2,400,000 | $2,171,000 | $1,721,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $25,375,000 | $41,819,000 | $84,558,000 | $80,294,000 |
| Total Non Current Liabilities Net Minority Interest | $88,000 | $2,740,000 | $5,939,000 | $45,205,000 |
| Non Current Deferred Liabilities | $0 | $1,730,000 | $2,682,000 | $39,613,000 |
| Current Liabilities | $25,287,000 | $39,079,000 | $78,619,000 | $35,089,000 |
| Other Current Liabilities | $166,000 | $194,000 | $271,000 | $377,000 |
| Current Deferred Liabilities | $0 | $10,222,000 | $53,102,000 | $11,921,000 |
| Payables And Accrued Expenses | $17,659,000 | $19,282,000 | $17,459,000 | $16,203,000 |
| Payables | $3,623,000 | $2,400,000 | $1,701,000 | $2,825,000 |
| Accounts Payable | $3,623,000 | $2,400,000 | $461,000 | $2,302,000 |
| Total Tax Payable | - | $0 | $1,240,000 | $523,000 |
| Income Tax Payable | - | $0 | $1,240,000 | $523,000 |
| Equity | ||||
| Common Stock Equity | $151,131,000 | $212,082,000 | $279,517,000 | $288,421,000 |
| Total Equity Gross Minority Interest | $151,131,000 | $212,082,000 | $279,517,000 | $288,421,000 |
| Stockholders Equity | $151,131,000 | $212,082,000 | $279,517,000 | $288,421,000 |
| Other Equity Interest | $10,000 | - | - | - |
| Gains Losses Not Affecting Retained Earnings | $54,000 | $28,000 | $-428,000 | $0 |
| Other Equity Adjustments | $54,000 | $28,000 | $-428,000 | - |
| Retained Earnings | $-417,798,000 | $-333,109,000 | $-239,313,000 | $-210,266,000 |
| Other | ||||
| Ordinary Shares Number | $42,510,708 | $42,176,041 | $42,036,193 | $41,850,162 |
| Share Issued | $42,510,708 | $42,176,041 | $42,036,193 | $41,850,162 |
| Tangible Book Value | $151,131,000 | $212,082,000 | $279,517,000 | $288,421,000 |
| Invested Capital | $151,131,000 | $212,082,000 | $279,517,000 | $288,421,000 |
| Working Capital | $145,862,000 | $204,609,000 | $275,360,000 | $316,325,000 |
| Capital Lease Obligations | $1,933,000 | $3,410,000 | $5,428,000 | $7,313,000 |
| Total Capitalization | $151,131,000 | $212,082,000 | $279,517,000 | $288,421,000 |
| Additional Paid In Capital | $82,191,000 | $61,813,000 | $37,226,000 | $17,988,000 |
| Capital Stock | $486,674,000 | $483,350,000 | $482,032,000 | $480,699,000 |
| Common Stock | $486,674,000 | $483,350,000 | $482,032,000 | $480,699,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $1,730,000 | $2,682,000 | $39,613,000 |
| Long Term Capital Lease Obligation | $88,000 | $1,010,000 | $3,257,000 | $5,592,000 |
| Current Deferred Revenue | $0 | $10,222,000 | $53,102,000 | $11,921,000 |
| Current Capital Lease Obligation | $1,845,000 | $2,400,000 | $2,171,000 | $1,721,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,617,000 | $6,981,000 | $5,616,000 | $4,867,000 |
| Current Accrued Expenses | $14,036,000 | $16,882,000 | $15,758,000 | $13,378,000 |
| Net PPE | $4,218,000 | $7,541,000 | $9,599,000 | $13,095,000 |
| Accumulated Depreciation | $-9,204,000 | $-7,304,000 | $-5,353,000 | $-3,375,000 |
| Gross PPE | $13,422,000 | $14,845,000 | $14,952,000 | $16,470,000 |
| Leases | $2,547,000 | $2,547,000 | $2,519,000 | $2,465,000 |
| Other Properties | $9,888,000 | $11,311,000 | $11,446,000 | $13,027,000 |
| Machinery Furniture Equipment | $987,000 | $987,000 | $987,000 | $978,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $68,074,000 | $112,359,000 | $184,420,000 | $7,439,000 |
| Treasury Shares Number | - | $0 | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-76,445,000 | $-129,096,000 | $-280,000 | $-87,486,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-76,445,000 | $-127,158,000 | $322,000 | $-85,796,000 |
| Cash Flow From Continuing Operating Activities | $-76,445,000 | $-127,158,000 | $322,000 | $-85,796,000 |
| Operating Gains Losses | $8,000 | $78,000 | $-298,000 | $36,000 |
| Investing Activities | ||||
| Investing Cash Flow | $49,468,000 | $78,041,000 | $-175,778,000 | $-1,676,000 |
| Cash Flow From Continuing Investing Activities | $49,468,000 | $78,041,000 | $-175,778,000 | $-1,676,000 |
| Capital Expenditure | - | $-1,938,000 | $-602,000 | $-1,690,000 |
| Financing Activities | ||||
| Financing Cash Flow | $542,000 | $842,000 | $880,000 | $95,557,000 |
| Cash Flow From Continuing Financing Activities | $542,000 | $842,000 | $880,000 | $95,557,000 |
| Issuance Of Capital Stock | - | - | $0 | $94,288,000 |
| Net Common Stock Issuance | - | - | $0 | $94,288,000 |
| Common Stock Issuance | - | - | $0 | $94,288,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $139,000 | $4,945,000 | $10,810,000 | $25,000 |
| End Cash Position | $84,717,000 | $111,268,000 | $159,521,000 | $334,427,000 |
| Beginning Cash Position | $111,268,000 | $159,521,000 | $334,427,000 | $326,396,000 |
| Effect Of Exchange Rate Changes | $-116,000 | $22,000 | $-330,000 | $-54,000 |
| Changes In Cash | $-26,435,000 | $-48,275,000 | $-174,576,000 | $8,085,000 |
| Proceeds From Stock Option Exercised | $542,000 | $842,000 | $880,000 | $1,269,000 |
| Net Investment Purchase And Sale | $49,468,000 | $79,979,000 | $-175,176,000 | $-26,000 |
| Sale Of Investment | $182,823,000 | $259,000,000 | $81,400,000 | $7,450,000 |
| Purchase Of Investment | $-133,355,000 | $-179,021,000 | $-256,576,000 | $-7,476,000 |
| Net PPE Purchase And Sale | $0 | $-1,938,000 | $-602,000 | $-1,650,000 |
| Purchase Of PPE | $0 | $-1,938,000 | $-602,000 | $-1,690,000 |
| Change In Working Capital | $-14,057,000 | $-55,183,000 | $8,025,000 | $4,790,000 |
| Change In Other Working Capital | $-10,423,000 | $-58,161,000 | $7,870,000 | $-8,681,000 |
| Change In Other Current Liabilities | $-2,311,000 | $-2,222,000 | $-1,531,000 | $-1,020,000 |
| Change In Other Current Assets | $217,000 | $101,000 | $89,000 | $-298,000 |
| Change In Payables And Accrued Expense | $-2,993,000 | $4,346,000 | $2,389,000 | $11,823,000 |
| Change In Accrued Expense | $-4,222,000 | $2,412,000 | $3,020,000 | $11,166,000 |
| Change In Payable | $1,229,000 | $1,934,000 | $-631,000 | $657,000 |
| Change In Account Payable | $1,229,000 | $1,934,000 | $-1,348,000 | $152,000 |
| Change In Prepaid Assets | $-1,263,000 | $969,000 | $593,000 | $-32,000 |
| Change In Receivables | $2,716,000 | $-216,000 | $-1,385,000 | $2,998,000 |
| Other Non Cash Items | $2,359,000 | $2,194,000 | $2,206,000 | $1,873,000 |
| Stock Based Compensation | $23,170,000 | $25,063,000 | $19,691,000 | $12,829,000 |
| Amortization Of Securities | $-5,157,000 | $-7,465,000 | $-2,233,000 | $113,000 |
| Depreciation Amortization Depletion | $1,921,000 | $1,951,000 | $1,978,000 | $1,471,000 |
| Depreciation And Amortization | $1,921,000 | $1,951,000 | $1,978,000 | $1,471,000 |
| Depreciation | $1,921,000 | $1,951,000 | $1,978,000 | $1,471,000 |
| Net Foreign Currency Exchange Gain Loss | $8,000 | $78,000 | $-298,000 | $12,000 |
| Net Income From Continuing Operations | $-84,689,000 | $-93,796,000 | $-29,047,000 | $-106,908,000 |
| Change In Tax Payable | - | $-14,329,000 | $717,000 | $505,000 |
| Change In Income Tax Payable | - | $-14,329,000 | $717,000 | $505,000 |
| Sale Of PPE | - | - | $0 | $40,000 |
| Changes In Account Receivables | - | - | $-1,525,000 | $0 |
| Gain Loss On Sale Of PPE | - | - | $0 | $24,000 |
Fetched: 2026-02-02